03:50 PM EST, 02/06/2026 (MT Newswires) -- Health care stocks rose late Friday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.8%.

The iShares Biotechnology ETF (IBB) climbed 2.8%.

In corporate news, the US Food and Drug Administration will "take swift action against companies mass-marketing illegal copycat drugs" of FDA-approved products, FDA Commissioner Marty Makary said in a late Thursday post on social media platform X. Reuters reported Friday that the announcement followed Hims & Hers Health's ( HIMS ) launch of a cheaper alternative to Novo Nordisk's ( NVO ) FDA-approved Wegovy pill. Novo shares jumped past 9%, and Hims & Hers fell 1.8%.

Gilead Sciences' ( GILD ) Kite said Friday the US Food and Drug Administration approved an update to the prescribing label for Yescarta, removing a prior limitation on use in patients with relapsed or refractory primary central nervous system lymphoma. Gilead shares gained 2.1%.

Pulse Biosciences ( PLSE ) shares surged 47% after the company said clinical data from its nPulse cardiac catheter feasibility study showed successful treatment of atrial fibrillation in 150 people with "rapid" procedure times and minimal adverse effects.

SpyGlass Pharma ( SGP ) shares soared 62% in their Nasdaq debut after the company raised about $150 million in its IPO.